Astec LifeSciences Limited — Updates, 30-01-2026: Press Release
30-01-2026 | 08:43 pm
30-01-2026 | 08:43 pm
Astec LifeSciences announced its Q3/9M FY26 results. Q3 consolidated income rose 31% to Rs. 125.5 Cr, with EBITDA turning positive at Rs. 4.8 Cr from a loss. Net loss significantly reduced to Rs. 15.7 Cr. Strong revenue growth driven by higher Enterprise and CDMO volumes.
No comments yet. Be the first to comment!
